BACKGROUND: The safety and optimal use of prophylactic treatment with low-molecular-weight heparins in elderly patients with impaired renal function remain undefined. METHODS: The primary aim of this study was to analyse, in 'real life', the influence of renal function, as assessed by creatinine clearance (CL(CR)), on the level of anti-Xa activity in medical hospitalised elderly patients receiving prophylactic dosages of enoxaparin. Consecutive hospitalised acutely ill medical patients aged >or=75 years receiving daily dosages of enoxaparin 4000 IU for up to 10 days were prospectively enrolled in two centres. Peak anti-Xa activity was measured at the beginning and during the course of therapy. RESULTS: One hundred and twenty-five patients (31 men, 94 women), mean age 87.5 +/- 6.3 years, mean bodyweight 56.4 +/- 11.9 kg and mean CL(CR) 39.8 +/- 16.1 mL/min, were enrolled in the study. The mean maximum anti-Xa activity (day 1 to day 10) [anti-Xa(max1-10)] was 0.64 +/- 0.23 IU/mL (range 0.24-1.50 IU/mL). Weak negative correlations were found between CL(CR) and anti-Xa(max) and between bodyweight and anti-Xa(max). Mean anti-Xa(max) was slightly but significantly higher in patients with CL(CR) of 20-30 mL/min compared with patients with CL(CR) of 31-40, 41-50 or 51-80 mL/min (0.72 versus 0.61, 0.61 and 0.60 IU/mL, respectively), and in patients weighing <50 kg compared with patients weighing 50-60 kg or >60 kg (0.74 vs 0.64 and 0.52 IU/mL, respectively). Serious bleeding occurred in five patients, but anti-Xa(max) values in these patients were not different to those in patients without bleeding (p = 0.77). Individual anti-Xa(max) at the beginning or during the course of treatment was measured in the subgroup of 58 patients in whom anti-Xa activity was measured at least once during the study. The mean anti-Xa(max) value was slightly but significantly higher during the course of the therapy than at the beginning of the study (0.63 +/- 0.26 IU/mL vs 0.56 +/- 0.23 IU/mL, p = 0.012). CONCLUSION: Only CL(CR) <30 mL/min and bodyweight <50 kg were associated with significantly higher anti-Xa(max) values. The clinical relevance of these increases remains questionable. No conclusions about the safety of enoxaparin in elderly medical patients can be drawn from these findings.
BACKGROUND: The safety and optimal use of prophylactic treatment with low-molecular-weight heparins in elderly patients with impaired renal function remain undefined. METHODS: The primary aim of this study was to analyse, in 'real life', the influence of renal function, as assessed by creatinine clearance (CL(CR)), on the level of anti-Xa activity in medical hospitalised elderly patients receiving prophylactic dosages of enoxaparin. Consecutive hospitalised acutely ill medical patients aged >or=75 years receiving daily dosages of enoxaparin 4000 IU for up to 10 days were prospectively enrolled in two centres. Peak anti-Xa activity was measured at the beginning and during the course of therapy. RESULTS: One hundred and twenty-five patients (31 men, 94 women), mean age 87.5 +/- 6.3 years, mean bodyweight 56.4 +/- 11.9 kg and mean CL(CR) 39.8 +/- 16.1 mL/min, were enrolled in the study. The mean maximum anti-Xa activity (day 1 to day 10) [anti-Xa(max1-10)] was 0.64 +/- 0.23 IU/mL (range 0.24-1.50 IU/mL). Weak negative correlations were found between CL(CR) and anti-Xa(max) and between bodyweight and anti-Xa(max). Mean anti-Xa(max) was slightly but significantly higher in patients with CL(CR) of 20-30 mL/min compared with patients with CL(CR) of 31-40, 41-50 or 51-80 mL/min (0.72 versus 0.61, 0.61 and 0.60 IU/mL, respectively), and in patients weighing <50 kg compared with patients weighing 50-60 kg or >60 kg (0.74 vs 0.64 and 0.52 IU/mL, respectively). Serious bleeding occurred in five patients, but anti-Xa(max) values in these patients were not different to those in patients without bleeding (p = 0.77). Individual anti-Xa(max) at the beginning or during the course of treatment was measured in the subgroup of 58 patients in whom anti-Xa activity was measured at least once during the study. The mean anti-Xa(max) value was slightly but significantly higher during the course of the therapy than at the beginning of the study (0.63 +/- 0.26 IU/mL vs 0.56 +/- 0.23 IU/mL, p = 0.012). CONCLUSION: Only CL(CR) <30 mL/min and bodyweight <50 kg were associated with significantly higher anti-Xa(max) values. The clinical relevance of these increases remains questionable. No conclusions about the safety of enoxaparin in elderly medical patients can be drawn from these findings.
Authors: Alexander T Cohen; Bruce L Davidson; Alexander S Gallus; Michael R Lassen; Martin H Prins; Witold Tomkowski; Alexander G G Turpie; Jan F M Egberts; Anthonie W A Lensing Journal: BMJ Date: 2006-01-26
Authors: M Laposata; D Green; E M Van Cott; T W Barrowcliffe; S H Goodnight; R C Sosolik Journal: Arch Pathol Lab Med Date: 1998-09 Impact factor: 5.534
Authors: Louis Desjardins; Lucienne Bara; Florent Boutitie; Meyer Michel Samama; Alexander T Cohen; Sophie Combe; Charles Janbon; Alain Leizorovicz; Carl-Gustav Olsson; Alexander G G Turpie Journal: Arch Pathol Lab Med Date: 2004-05 Impact factor: 5.534
Authors: Edmund J Lamb; Michelle C Webb; David E Simpson; Anthony J Coakley; David J Newman; Shelagh E O'Riordan Journal: J Am Geriatr Soc Date: 2003-07 Impact factor: 5.562
Authors: J C Easaw; M A Shea-Budgell; C M J Wu; P M Czaykowski; J Kassis; B Kuehl; H J Lim; M MacNeil; D Martinusen; P A McFarlane; E Meek; O Moodley; S Shivakumar; V Tagalakis; S Welch; P Kavan Journal: Curr Oncol Date: 2015-04 Impact factor: 3.677
Authors: Frederick Leri; Stephen J Voyce; Salvatore Scialla; William Glavich; Edward Dzielak; Raymond A Smego; John Guzek Journal: J Thromb Thrombolysis Date: 2009-03-13 Impact factor: 2.300
Authors: B Dufour; M Toussaint-Hacquard; A Kearney-Schwartz; M D P Manckoundia; M C Laurain; L Joly; J Deibener; D Wahl; T Lecompte; A Benetos; C Perret-Guillaume Journal: J Nutr Health Aging Date: 2012-07 Impact factor: 4.075